The German-French X-BAT consortium focuses on the research on and generation of a decavalent equine antitoxin counteracting deliberate attacks with all currently known botulinum neurotoxin types. By means of innovative antigen design and state-of-the-art production new routes in the generation of sufficient volumes of life saving BoNT antitoxin are explored. The consortium aims at providing a highly available, EU-licensable treatment of civilians and civil security forces upon deliberate BoNT intoxications.
X-BAT is being funded by the Agence Nationale de la Recherche (ANR) and the German Federal Ministry of Education and Research (BMBF) within the framework of the Franco-German cooperation in security research.
